![MERZ [Logo]](/media/layout_1/img/skin_logo-screen.gif){kind=logo}
Facts and Figures
| Headquarters: | Frankfurt am Main, Germany |
| Branch Offices: | Germany, Great Britain, Brazil, France, Italy, Spain, Switzerland, Austria, USA, Mexico, Russia, Canada, Korea, Singapore, Taiwan, |
| Status: | Private company |
| Fiscal Year: | July 1 - June 30 |
| Key Figures of the Merz Group | ||||
|---|---|---|---|---|
| 2010/11 | 2009/10 | Change in % | ||
| Revenue | EUR million | 780.4 | 649.6 | 20.1 |
| of which: | ||||
| Pharmaceuticals | EUR million | 683.5 | 558.7 | 22.3 |
| Consumer Care | EUR million | 67.1 | 62.9 | 6.7 |
| Dental/Hygiene | EUR million | 20.7 | 19.6 | 5.6 |
| Merz Group Services | EUR million | 9.1 | 8.4 | 8.3 |
| of which: | ||||
| Germany | EUR million | 163.0 | 164.5 | – 0.9 |
| Rest of Europe | EUR million | 238.6 | 191.1 | 24.9 |
| America | EUR million | 347.4 | 273.0 | 27.3 |
| Other regions | EUR million | 31.4 | 21.0 | 49.5 |
| Results of operation | ||||
| EBIT | EUR million | 168.2 | 153.0 | 9.9 |
| EBIT-margin | % | 21.4 | 23.6 | |
| EBT (earnings before tax) | EUR million | 166.6 | 150.6 | 10.6 |
| Profit for the year | EUR million | 112.9 | 106.3 | 6.2 |
| Cash flow from operating activities | EUR million | 239.4 | 148.2 | 61.5 |
| Research and development | ||||
| Research and development expenses | EUR million | 133.4 | 130.1 | 2.5 |
| as % of revenue | % | 17.1 | 20.0 | |
| of which Pharmaceuticals | EUR million | 129.1 | 125.5 | 2.9 |
| Financial position and net assets | ||||
| Acquisitions | EUR million | 0.0 | 190.5 | |
| Capital expenditure | EUR million | 10.7 | 16.9 | – 36.7 |
| Amortization and depreciation | EUR million | 20.1 | 16.1 | 24.8 |
| Total assets | EUR million | 624.5 | 743.2 | – 16.0 |
| Employees | ||||
| Headcount as of the end of the reporting period | 2,391 | 2,131 | 12.2 | |
Download Annual Report (2166 KB)
Most Important Products of Merz Pharmaceuticals:
- Axura® (Alzheimer’s)
- PK-Merz® (Parkinson’s)
- Solvex® (depression)
- Contractubex® / Mederma® (scars)
- Naftin® (fungal diseases)
- Pantogar® / Pantovigar® (hair loss)
- Pantostin® (hair loss)
- Hyal-System® (wrinkles)
- Belotero® (wrinkles)
- Hepa-Merz® (liver-related brain impairment)
- Lipo-Merz retard® (lipid metabolism disorders)
- Xeomin® (Blepharospasm; cervical dystonia of a predominantly rotational form)
- Bocouture® (wrinkles)
Most Important Consumer Care Brands:
- tetesept® (OTC drugs)
- Merz Spezial® (beauty care)
Shareholders´council:
- Dr. Jochen Hückmann
Supervisory Board:
- Andreas Krebs, Chairman
- Michael Freiherr von Truchseß, assistant Chairman
- Prof. Dr. Dr. h.c. Rolf Krebs
- Prof. Dr. Harald Wiedmann
Merz Management Board (MMB):
- Dr. Martin Zügel, Chairman of the Management Board
- Hartmut Erlinghagen
- Dr. Matthias A. Vogt
Login for Professionals
- © 2012 Merz Pharma |
- Privacy Policy |
- Terms of Use |
- Imprint |
- General Terms and Conditions of Purchase
last update 15. Mai 2012, 10:20 Uhr
produced by GPM mbH
![Merz [Logo]](/media/layout_1/img/base_logo-print.gif){kind=logo}